NKG2D and its ligands in cancer

Current Opinion in Immunology

Volumn 51, Issue , 2018, Pages 55-61

  Dhar, Payal ^a   Wu, Jennifer D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; CHIMERIC ANTIGEN RECEPTOR; HISTONE DEACETYLASE INHIBITOR; MICA PROTEIN; MICB PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG; LIGAND; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING;

CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CROSS PRESENTATION; DENDRITIC CELL; DNA DAMAGE; DRUG TARGETING; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; NATURAL KILLER CELL; NONHUMAN; OPSONIZATION; PROSTATE TUMOR; REVIEW; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANIMAL; DISEASE PREDISPOSITION; GENETICS; IMMUNE EVASION; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE SUSCEPTIBILITY; HUMANS; IMMUNE EVASION; IMMUNOTHERAPY, ADOPTIVE; LIGANDS; LYMPHOCYTE SUBSETS; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 85043330243     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2018.02.004     Document Type: Review

References (78)

1. Raulet, D.H., Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3 (2003), 781–790.
2. Zhang, J., Basher, F., Wu, J.D., NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol, 6, 2015, p97.
3. Bauer, S., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999), 727–729.
4. Groh, V., et al. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2 (2001), 255–260.
5. Champsaur, M., Lanier, L.L., Effect of NKG2D ligand expression on host immune responses. Immunol Rev 235 (2010), 267–285.
6. Le Bert, N., Gasser, S., Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol 92 (2014), 230–236.
7. Eagle, R.A., Trowsdale, J., Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 7 (2007), 737–744.
8. El-Gazzar, A., Groh, V., Spies, T., Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer. J Immunol 191 (2013), 1509–1515.
9. Baragano Raneros, A., Suarez-Alvarez, B., Lopez-Larrea, C., Secretory pathways generating immunosuppressive NKG2D ligands: new targets for therapeutic intervention. Oncoimmunology, 3, 2014, e28497.
10. Maccalli, C., et al. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. Oncoimmunology, 6, 2017, e1323618 This study describes that serum soluble NKG2D-L in melanoma patients before therapy correlated with reduced survival in response to immune checkpoint blockade therapy, suggesting that serum sNKG2D-L can be biomarker to select melanoma patients for immune checkpoint therapy.
11. Zhang, J., et al. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. Sci Adv, 3, 2017, e1602133 Two major findings in this pre-clinical study using clinically relevant animal model: high levels of serum sMIC at base level induce colitis in response to anti-CTLA therapy and confer poor tumor response; and antibody clearing sMIC significantly enhanced tumor response to anti-CTLA4 therapy and alleviated colitis. The findings suggest that cancer patients should be pre-screened for serum sMIC to select better responders. The study also endorsed a new combination immunotherapy.
12. Kumar, V., et al. Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. PLoS ONE, 7, 2012, e44743.
13. Tamaki, S., et al. Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res 30 (2010), 4097–4101.
14. Vyas, M., et al. Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology, 6, 2017, e1339854.
15. Tamaki, S., et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol 69 (2008), 88–93.
16. Nausch, N., Cerwenka, A., NKG2D ligands in tumor immunity. Oncogene 27 (2008), 5944–5958.
17. Garrity, D., et al. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A 102 (2005), 7641–7646.
18. Wu, J., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 (1999), 730–732.
19. Ogasawara, K., Lanier, L.L., NKG2D in NK and T cell-mediated immunity. J Clin Immunol 25 (2005), 534–540.
20. Lanier, L.L., et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391 (1998), 703–707.
21. Diefenbach, A., et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3 (2002), 1142–1149.
22. McFarland, B.J., et al. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 11 (2003), 411–422.
23. Radaev, S., et al. Making sense of the diverse ligand recognition by NKG2D. J Immunol 169 (2002), 6279–6285.
24. Kraetzel, K., et al. NKG2D-dependent effector function of bronchial epithelium-activated alloreactive T-cells. Eur Respir J 32 (2008), 563–570.
25. Hue, S., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21 (2004), 367–377.
26. Wu, J., et al. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 170 (2003), 4196–4200.
27. Cerwenka, A., et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12 (2000), 721–727.
28. Diefenbach, A., et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1 (2000), 119–126.
29. Carayannopoulos, L.N., et al. Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 169 (2002), 4079–4083.
30. Takada, A., et al. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D. J Immunol 180 (2008), 1678–1685.
31. Lanier, L.L., NKG2D receptor and its ligands in host defense. Cancer Immunol Res 3 (2015), 575–582.
32. Venkataraman, G.M., et al. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J Immunol 178 (2007), 961–969.
33. Gasser, S., Raulet, D.H., Activation and self-tolerance of natural killer cells. Immunol Rev 214 (2006), 130–142.
34. Armeanu, S., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65 (2005), 6321–6329.
35. Miyashita, T., et al. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B. Oncol Lett 14 (2017), 5918–5926 Major finding: low dose HDAC inhibitor (valproic acid) and low-dose nucleoside analogue chemoreagent synergistically upregulate MIC/A expression in MICA/B-positive pancreatic tumor cells without inducing MIC shedding to sensitize pancreatic tumor to NKG2D-mediated cell cytotoxicity. The findings suggest epigenetic modification of NKG2D pathway may be combined with immunotherapy for treating pancreatic cancer.
36. Shi, P., et al. Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. BMC Cancer, 14, 2014, 370.
37. Wu, X., et al. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia 14 (2012), 1178–1189.
38. Yamanegi, K., et al. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. Oncol Rep 24 (2010), 1621–1627.
39. Yang, F., et al. Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci 9 (2013), 323–331.
40. Nakajima, N.I., et al. Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells. Oncol Rep 38 (2017), 693–702 Major finding: inhibitors to HDAC pathway can re-sensitive tumor cells that are non-response to IR-induction of MICA/B expression. The findings suggest that inhibition of HDAC pathway with low-dose IR can potentiate immunotherapy to control tumors.
41. Weiss, T., et al. NKG2D-dependent anti-tumor effects of chemotherapy and radiotherapy against glioblastoma. Clin Cancer Res, 2017 This study demonstrates standard care with temozolomide and radiotherapy induces NKG2D-L expression on primary and recurrent glioblastoma cells and confers survival benefit in pre-clinical models. The study provides a rationale to combine NKG2D-based immunotherapies with TMZ and IR for glioblastoma.
42. Stern-Ginossar, N., et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9 (2008), 1065–1073.
43. Breunig, C., et al. MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells. Cell Death Dis, 8, 2017, e2973.
44. Kishikawa, T., et al. Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs. Sci Rep, 3, 2013, 2739.
45. Zhao, Y.K., et al. Expression and clinical value of the soluble major histocompatibility complex class I-related chain A molecule in the serum of patients with renal tumors. Genet Mol Res 14 (2015), 7233–7240.
46. Holdenrieder, S., et al. Soluble MICA in malignant diseases. Int J Cancer 118 (2006), 684–687.
47. Wu, J.D., et al. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114 (2004), 560–568.
48. Paschen, A., et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 15 (2009), 5208–5215.
49. Li, K., et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58 (2009), 641–652.
50. Nuckel, H., et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 24 (2010), 1152–1159.
51. Wang, R., Sun, P.D., Natural killer cell-mediated shedding of ULBP2. PLoS ONE, 9, 2014, e91133.
52. Yamaguchi, K., et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci 103 (2012), 1405–1413.
53. Cerwenka, A., Baron, J.L., Lanier, L.L., Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 98 (2001), 11521–11526.
54. Diefenbach, A., et al. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001), 165–171.
55. Smyth, M.J., et al. NKG2D function protects the host from tumor initiation. J Exp Med 202 (2005), 583–588.
56. Guerra, N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008), 571–580.
57. McGilvray, R.W., et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15 (2009), 6993–7002.
58. Vetter, C.S., et al. Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol 118 (2002), 600–605.
59. Vetter, C.S., et al. Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. Br J Cancer 91 (2004), 1495–1499.
60. Oppenheim, D.E., et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6 (2005), 928–937.
61. Wiemann, K., et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 175 (2005), 720–729.
62. Liu, G., et al. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest 123 (2013), 4410–4422.
63. Groh, V., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002), 734–738.
64. Hanaoka, N., et al. NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol 185 (2010), 5732–5742.
65. Xiao, G., et al. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J Hematol Oncol, 8, 2015, 13 The study demonstrated that sNKG2D-L, sMIC, can skew myeloid cell differentiation to more immune suppressive phenotypes and uncovers a new mechanism whereby sMIC is immune suppressive.
66. Wang, X., et al. An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit shedding. Biochem Biophys Res Commun 387 (2009), 476–481.
67. Kaiser, B.K., et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447 (2007), 482–486.
68. Weil, S., et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol, 8, 2017, 387 The study demonstrated that highly levels of sNKG2D-L prevent NK cell infiltration into HNSCC tumors and suggest the removal of plasma sNKG2D-L will pre-condition HNSCC patient for better outcome of cellular cancer immunotherapy.
69. Lu, S., et al. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clin Cancer Res 21 (2015), 4819–4830 The study demonstrated that antibody clearance of sMIC can revive host innate and adoptive immune response and debulk established primary tumors and eliminate metastasis. The finding provides proof-of-concept that sMIC is a viable target for cancer immunotherapy.
70. Basher, F., et al. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC. Oncotarget 7 (2016), 814–830.
71. Sentman, C.L., Meehan, K.R., NKG2D CARs as cell therapy for cancer. Cancer J 20 (2014), 156–159.
72. Barber, A., et al. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Exp Hematol 36 (2008), 1318–1328.
73. Barber, A., et al. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res 67 (2007), 5003–5008.
74. − (4-1BB-CD3 platform) memory T cells exert potent and safe antitumor activity to primary and rechallenged tumors. The findings provide the rationale to treatment patients with osteosarcoma with NKG2D-CAR redirected memory T cells.
75. Chang, Y.H., et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res 73 (2013), 1777–1786.
76. VanSeggelen, H., et al. T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Mol Ther 23 (2015), 1600–1610.
77. Sentman, M.L., et al. Mechanisms of acute toxicity in NKG2D chimeric antigen receptor T cell-treated mice. J Immunol 197 (2016), 4674–4685.
78. Lonez, C., et al. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open, 7, 2017, e017075.